Navigation Links
Monoclonal antibodies show promise in treatment of blood cancer

Immunologists at Duke University Medical Center have found that a new monoclonal antibody that targets immune system B cells could be a pioneering treatment for leukemias, autoimmune diseases and transplant rejection//.

B cells are the main producers of antibodies, the body's defense mechanism against invading antigens. But the uncontrolled production of these B cells is responsible for leukemias such as multiple myeloma and acute lymphoblastic leukemia and autoimmune diseases like rheumatoid arthritis and lupus. The findings of the study have been published in the online Early Edition of the Proceedings of the National Academy of Sciences for the week October 10, 2005.

Professor and Chair of Immunology Thomas Tedder, Ph.D., Norhito Yazawa, Yasuhito Hamaguchi and Jonathan Poe in Tedder's laboratory are the co-authors of this report. Basically, monoclonal antibodies are directed against specific proteins. In this study, the Duke researchers targeted a surface protein called CD19, which is found on the B cells. When this was administered to laboratory mice, the researchers found that this reduced the number of B cells greatly. Significantly they also found that this monoclonal antibody behaved aggressively against B cell tumors. In 10 mice with malignant B cell lymphomas, the monoclonal antibody prevented the appearance of tissue tumor circulating cells for seven weeks. In contrast untreated mice died in three weeks. "We were actually quite shocked at how effectively CD19 mAb-treatments prevented malignant B cell expansion," said Tedder. "Treatment of such tumors in mouse models is extraordinarily difficult." Based on their findings, the researchers conclude, "In addition, this treatment could greatly aid transplant patients who require multiple organ transplants because they develop a humoral antibody response to their transplanted organs, or they already have preformed antibodies that prevent them from accepting some donor grafts."
'"/>




Page: 1

Related medicine news :

1. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
2. Monoclonal Anti-Body To Revolutionize Brain Cancer Treatment
3. Monoclonal Antibody based system for Anthrax detection
4. Monoclonal Antibody Reduces Exacerbations in Asthmatics
5. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
6. Mutating viruses helps produce antibodies
7. Hybrid antibodies to protect from small pox infection
8. Gene Therapy shows promise in treating Hemophilia
9. Leukemia pill shows promise against stomach cancer
10. Stent shows promise in keeping arteries open
11. Drug to treat lung cancer shows promise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/5/2016)... ... May 05, 2016 , ... Einstein Medical is ... to cover the latest news and commentary at the 2016 ASCRS/ASOA Symposium and Congress, ... the American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to long-term warfarin medication ... offering the procedure in April of 2015, Florida Hospital Pepin Heart Institute doctors ...
(Date:5/5/2016)... ... 05, 2016 , ... TLC Laser Eye Centers announced today that it has ... will now be called “Gordon Schanzlin New Vision Institute, a TLC Laser Eye Center.” ... facility to ensure that patients continue to receive the highest quality of care. In ...
(Date:5/5/2016)... ... ... weekend, from Friday, May 6 - Sunday, May 8, fifteen elite athletes from Team ... Fi Mountain Bike Camp, hosted in conjunction with WTB and Cannondale ... Moeschler, who’ll share pro tips with the injured veterans as they rip down some of ...
(Date:5/5/2016)... SAN FRANCISCO (PRWEB) , ... May 05, 2016 ... ... in the Unites States to promise successful results with IVF and with egg ... Designed to deliver the most patient-centric and highest quality fertility care, Spring Fertility ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 5, 2016  Endo International plc (NASDAQ: ... Brian Lortie , President, U.S. Branded Pharmaceuticals, ... upon the appointment of a successor. Mr. Lortie ... Pharmaceuticals business with responsibility for all strategic, commercial ... and portfolio development, commercial operations, managed markets, manufacturing, ...
(Date:5/5/2016)... Endo International plc (NASDAQ: ENDP ) (TSX: ENL) ... former president of Allergan, Inc. and current CEO of Chase ... of TPG Capital, to its Board of Directors. The appointments ... "Endo recently embarked on a search for new Board members ... Doug and Todd are experienced leaders, and we are extremely ...
(Date:5/5/2016)... First quarter 2016 adjusted diluted earnings per share (EPS) ... First quarter reported diluted (GAAP) loss per share from ... 2016 financial guidance; now expects 2016 revenues to range from ... earnings per share to range from $4.50 to $4.80 ... manufacturing facility restructuring , Company expands Board ...
Breaking Medicine Technology: